Form 4: Elevance Health EVP Receives Significant Equity Awards

Elevance Health's EVP & Chief Legal Officer, Erin M. Wessling, was granted 931 restricted share units and options to purchase 3,541 shares of common stock.

Summary

• Erin M. Wessling, Executive Vice President & Chief Legal Officer of Elevance Health, Inc., was granted equity awards.
• The awards include 931 restricted share units (RSUs) of common stock, with a grant price of $0.
• These RSUs will vest in three annual installments: 310 shares on September 2, 2026, 310 shares on September 2, 2027, and 311 shares on September 2, 2028.
• Additionally, Ms. Wessling received employee stock options to purchase 3,541 shares of common stock at an exercise price of $322.33 per share.
• The stock options become exercisable in three annual installments, with two installments of 1,180 shares each and one installment of 1,181 shares, beginning on September 2, 2026, which is the one-year anniversary of the option grant date.
• The options have an expiration date of September 2, 2035.
• Following these transactions, Ms. Wessling beneficially owns 5,172 shares of common stock directly and 3,541 derivative securities (options) directly.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The filing reports a routine executive compensation grant, which is generally viewed positively as it aligns management's interests with shareholders and aids in executive retention. It does not indicate any operational or financial issues.

Positives

• The equity awards align the executive's financial interests with those of shareholders, promoting long-term value creation.
• The grants serve as a retention mechanism for a key executive, ensuring continuity in leadership.

Risks

• The value of the equity awards is subject to the future market performance of Elevance Health's common stock.
• The vesting and exercisability schedules mean the full benefit of the awards is not immediately realized and depends on continued employment.

Future Outlook

The future outlook indicates that the executive will gain full ownership of the restricted share units and the ability to exercise stock options over a multi-year vesting and exercisability schedule, contingent on continued employment and the company's performance.

Industry Context

The granting of restricted share units and stock options is a standard and widespread practice in executive compensation across various industries, particularly in large publicly traded companies like Elevance Health. This approach is designed to attract, retain, and motivate key executives by linking their compensation directly to the company's long-term performance and shareholder value.

Comparison to Industry Standards

• Equity awards, such as RSUs and stock options, are a common component of executive compensation packages in the healthcare and insurance sectors, aligning executive incentives with shareholder returns.
• The use of a Rule 10b5-1(c) plan for these transactions is a standard corporate governance practice to provide an affirmative defense against insider trading allegations by establishing pre-planned trading arrangements.

Corporate Governance

Related Party Transactions

• The equity grants to Erin M. Wessling, an executive officer, constitute a related party transaction as part of her compensation package.

Stakeholder Impact

• Shareholders: Potential positive impact through enhanced executive alignment with long-term company performance.
• Employees (Executive): Direct financial benefit through equity awards, subject to vesting and market conditions.

Next Steps

• The restricted share units will vest in three tranches on September 2, 2026, September 2, 2027, and September 2, 2028.
• The employee stock options will become exercisable in three annual installments starting September 2, 2026.

Key Dates

Recommendation

This Form 4 reports a routine equity compensation grant to a key executive, which is a standard practice for public companies. It does not provide new information that would fundamentally alter the investment outlook for Elevance Health, Inc. Therefore, a 'hold' recommendation is appropriate as the filing does not present a catalyst for a change in investment strategy.

Keywords

Elevance Health, ELV, Insider Transaction, Executive Compensation, Restricted Share Units, Stock Options, Equity Award, Form 4, Corporate Governance